5Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmaeogenetieally guided dosing [ J ]. Clin Pharmacokinet, 2007 ;46 : 187 - 208.
6Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines [ J ]. Eur J Clin Pharmacol, 2008 ; 64:753 - 767.
7Zhang JP, Zhou SF, Chen X, et al. Determination of intraethnic differences in the polymorphisms of thiopurine S - methyltransferase in Chinese [J]. Clin Chim Acta, 2006;365:337 -341.
8Zhou S. Clinical pharmacogenomics of thiopurine S - methyltransferase [J]. Curr Clin Pharmaco, 2006;1:119 -128.
9Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyhransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease [ J]. Aliment Pharmacol Ther, 2007; 25: 1069 - 1077.
10TANIS AA.Azathioprine in inflammatory bowel disease,a safe alternative[J].Mediators of Inflammation,1998,7(3):141.
